Jason Hoitt serves as Chief Patient Officer at Stoke Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering RNA modulation therapies for severe genetic diseases. In this role, he champions patient-centric strategies across the organization, integrating patient insights into drug discovery, clinical development, and commercialization to ensure therapies address unmet needs in rare neurological and other genetic disorders. His leadership fosters strong partnerships with patient advocacy groups, caregivers, and communities, amplifying their voices in decision-making processes. With more than 20 years in biotechnology and patient advocacy, Jason brings extensive expertise from prior roles at leading firms such as BioMarin Pharmaceutical and the Genetic Alliance. At BioMarin, he spearheaded global patient engagement programs for rare disease portfolios, optimizing clinical trial recruitment and retention, which accelerated enrollment by over 30% in key studies. His work has earned recognition, including awards for innovative stakeholder collaboration, and he has authored publications on patient-powered research. Under Jason's guidance at Stoke, initiatives like the Patient Advisory Council have directly shaped pipeline prioritization, including programs for Dravet syndrome and autosomal dominant optic atrophy. His vision emphasizes equitable access and long-term outcomes, positioning Stoke as a leader in patient-driven innovation within the genetic medicines space.